Neurofibromatosis Type 1 Clinical Trials

82 clinical trials for Neurofibromatosis Type 1 across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study — RECRUITING
• Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy) — RECRUITING
• A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 — RECRUITING · PHASE2
• Familial Investigations of Childhood Cancer Predisposition — RECRUITING
• A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1) — RECRUITING · NA
• Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence — RECRUITING · NA
• FARD (RaDiCo Cohort) (RaDiCo-FARD) — RECRUITING
• PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas — RECRUITING · PHASE1
• Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1 — RECRUITING
• A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma — ACTIVE_NOT_RECRUITING · PHASE3
• Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN — ACTIVE_NOT_RECRUITING · PHASE1
• Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1) — COMPLETED
• AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Neurofibromatosis Type 1 Tumor Early Detection Study — ACTIVE_NOT_RECRUITING
• Natural History Study of Patients With Neurofibromatosis Type I — ACTIVE_NOT_RECRUITING
• Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas — ACTIVE_NOT_RECRUITING · PHASE2
• Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 — COMPLETED
• Pediatric Long-Term Follow-up and Rollover Study — ACTIVE_NOT_RECRUITING · PHASE4
• Interventions for Reading Disabilities in NF1 — ACTIVE_NOT_RECRUITING · PHASE2
• Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas — ACTIVE_NOT_RECRUITING · PHASE1
• Gait in Young Children With NF1 — NOT_YET_RECRUITING
• PASS of Paediatric Patients Initiating Selumetinib — ACTIVE_NOT_RECRUITING
• Precision Medicine for Neurocutaneous Syndromes in Western China — COMPLETED
• Natural History Study of Cutaneous Neurofibromas in People With NF1 — ACTIVE_NOT_RECRUITING
• Function of the Pigment Epithelium in Patients With Type 1 Neurofibromatosis — COMPLETED
• Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach. — COMPLETED
• Neurobiology and Treatment of Reading Disability in NF-1 — COMPLETED · NA
• Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas — COMPLETED · PHASE2
• US Selumetinib Registry — TERMINATED
• Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma — COMPLETED · PHASE2
• MicroRNAs in Patients With Neurofibromatosis Type 1 — COMPLETED
• Molecular Aspects of Preimplantation Genetic Diagnosis for NF1 — COMPLETED
• Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery — COMPLETED · PHASE1
• Trametinib in neurofibromatosis type 1 related symptomatic plexiform neurofibromas — NOT_YET_RECRUITING · PHASE2
• Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments — COMPLETED
• Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours — COMPLETED · PHASE1
• Stem Cells in NF1 Patients With Tumors of the Central Nervous System — WITHDRAWN
• Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma — COMPLETED · PHASE2
• Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study — WITHDRAWN · PHASE2
• Selumetinib Paediatric NF1 Japan Study — COMPLETED · PHASE1
• Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest — OTHER
• Frameshift Peptides of Children With NF1 — COMPLETED
• Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain — COMPLETED · PHASE3
• Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1) — TERMINATED · PHASE2
• Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors — COMPLETED · PHASE1
• Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 — COMPLETED · NA
• Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1 — COMPLETED · NA
• Whole-body Vibration in Children With Neurofibromatosis Type 1 — COMPLETED · NA
• Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas — COMPLETED · PHASE2

Refine this search